Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
Mavatrep
Другие языки:

    Mavatrep

    Подписчиков: 0, рейтинг: 0
    Mavatrep
    Mavatrep.svg
    Clinical data
    Other names JNJ-39439335
    Identifiers
    • 2-[2-[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-3H-benzimidazol-5-yl]phenyl]propan-2-ol
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C25H21F3N2O
    Molar mass 422.451 g·mol−1
    3D model (JSmol)
    • CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)/C=C/C4=CC=C(C=C4)C(F)(F)F)O
    • InChI=1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+
    • Key:ORDHXXHTBUZRCN-NTEUORMPSA-N

    Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist. It is an investigational analgesic that may be a potential treatment for analgesia and/or inflammation.

    Phase I trials have been completed in healthy Japanese and Caucasian volunteers.

    Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.

    Pharmacokinetics

    When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days. It has a relatively long half life between 68–101 hours in Japanese subjects and between 82–130 hours in Caucasian subjects.

    Mavatrep is largely eliminated nonrenally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.


    Новое сообщение